Long-term outcomes of paclitaxel-coated balloons for non-malignant ureteral strictures
- 5 March 2022
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 40 (5) , 1231-1238
Abstract
Purpose To evaluate the clinical efficacy and safety of drug-coated balloon (DCB) ureteroplasty for the management of non-malignant ureteral strictures. Material and methods A prospective “off-label” monocentric single-arm pilot study investigating the safety and efficacy of drug-coated balloon (DCB) (Lutonix®; BD, USA) was performed. Twenty-five patients with benign ureteral strictures related to uretero-enteric anastomosis (n = 13); lithiasis (n = 5), post-surgical complications (iatrogenic n = 5), transplanted kidney (n = 1) and post-radiotherapy (n = 1) were included. Following lesion crossing, predilatation was performed using 4–7 mm high-pressure balloon catheter (5–6Fr) with a balloon pressure of 6–7 atm based on the manufacturer’s recommendation. In the absence of rupture of the ureteral wall, the DCB was dilated for 4 min. across the lesion. The process was repeated if deemed necessary to a maximum of three stricture dilatations. We analysed both clinical and radiological primary patency (no signs of ipsilateral hydronephrosis or improvement of the existing residual dilatation at the follow-up examinations) and secondarily safety endpoints. Results Mean lesion length was 40 ± 28.5 mm. Mean time follow up was 36 months ± 10.46 months. Strictures were located at upper ureteric (12%), lower ureteric (32%), ureterovesical anastomosis (4%) and uretero-enteric anastomosis (52%) levels. The overall radiological success at 1-year follow-up was 88% (22/25 patients). In 56% patients (14/25 patients with primary patency) the nephrostomy catheter was removed 21 days following a single DCB procedure. In 32% (8/25 patients) an additional dilatation sessions were required for maintaining the ureteral patency. The overall failure rate at 1-year follow-up was 12% (3/25 patients). Only one case of febrile urinary tract infection in a female patient (acute pyelonephritis) was encountered after the first dilatation. Conclusions Paclitaxel-coated balloon ureteroplasty proved to be safe and effective for the treatment of non-malignant ureteral strictures. Larger studies are warranted to validate these promising initial results.Keywords
This publication has 29 references indexed in Scilit:
- Paclitaxel Inhibits Ureteral Smooth Muscle Cell Proliferation and Collagen Production in the Absence of Cell ToxicityJournal of Urology, 2011
- Percutaneous Minimally Invasive Management of Iatrogenic Ureteral InjuriesJournal of Endourology, 2010
- Ureteral Complications in Renal Transplant Recipients Successfully Treated With Interventional RadiologyTransplantation Proceedings, 2008
- Percutaneous Therapy of Ureteral Obstructions and Leak After Renal Transplantation: Long-Term ResultsCardioVascular and Interventional Radiology, 2007
- Collagen Changes in the Ureteropelvic Junction after Failed Antegrade EndopyelotomyJournal of Endourology, 2007
- Distribution of the tight junction proteins ZO-1, occludin, and claudin-4, -8, and -12 in bladder epitheliumAmerican Journal of Physiology-Renal Physiology, 2004
- Long-Term Results of Endoureterotomy for Benign Ureteral and Ureteroenteric StricturesJournal of Urology, 1997
- Ureteral Cell Cultures II: Collagen Production and Response to Pharmacologic AgentsJournal of Urology, 1996
- Percutaneous balloon catheter dilatation of benign ureteral strictures: effect of multiple dilatation procedures on long-term patency.American Journal of Roentgenology, 1995
- Promotion of microtubule assembly in vitro by taxolNature, 1979